Regeneron Pharmaceuticals

Two drugs carry most of Regeneron Pharmaceuticals: Eylea, an eye injection that treats leading causes of vision loss in older adults, and Dupixent, an anti-inflammatory it developed and sells with partner Sanofi for eczema, asthma and related conditions. Dupixent in particular has become one of the best-selling medicines in the world, and Regeneron collects a share of its global sales. Founded in 1988 and based in Tarrytown, New York, the company is known for doing unusually deep in-house science, using genetically engineered mice and antibody technology to find new drugs rather than licensing them. That research engine has produced cancer and cholesterol treatments and a growing pipeline. The main risk is concentration: Eylea faces both biosimilar and branded competition, so investors watch closely whether newer products and a higher-dose version can offset any decline in that older franchise.

On MyRWA, REGN trades tokenized across 2 on-chain venues - see the listings below.